Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322211 | 0.83 | HSP90AB1 (0.57) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL13917686 | 0.82 | HSP90AB1 (0.55) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL4186399 | 0.82 | HSP90AB1 (0.59) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL4184134 | 0.79 | HSP90AB1 (0.66) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL31170815 | 0.78 | HSP90AB1 (0.57) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL3324933 | 0.78 | HSP90AB1 (0.57) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL3327824 | 0.78 | HSP90AB1 (0.61) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL3320527 | 0.78 | HSP90AB1 (0.75) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL31108382 | 0.78 | HSP90AB1 (0.75) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL3327826 | 0.76 | HSP90AB1 (0.66) | HSP90AB1HSP90AA1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069336-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | Dymock, Brian William (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069336-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | Dymock, Brian William (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069336-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | Dymock, Brian William (GB) | 2009-03-12 | — | — | US | disclosed |
| EP-1773842-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008503-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS (CAMBRIDGE) LTD (GB) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069336-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | ALK, NRAS, ROS1 | HSP90AB1 5/4885HSP90AA1 6/4885CYP2C19 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.